Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study
Psychopharmacology · 2024
DOI: 10.1007/s00213-024-06573-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology, 2024. Verfasst von Nathaniel A Shanok und 4 weiteren Autor:innen. Beteiligte Einrichtung: Delray Center for Brain Science, Delray Beach, FL, USA. nshanok@delraycenter.com. Hauptthemen laut MEDLINE: Ketamine, Major Depressive Disorder, Transcranial Magnetic Stimulation, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Major Depressive Disorder (MDD) is a pervasive psychiatric condition effecting approximately 21 million adults in the U.S. (8.4%). An estimated 30-60% of patients are resistant to traditional treatment approaches (medications and talk-therapy), alluding to the need for additional options. Two promising treatment modalities include transcranial magnetic stimulation (TMS) and ketamine infusions; both have shown efficacy in standalone studies but have scarcely been investigated synergistically in the same group of participants. METHOD: In the current study, 169 participants with treatment-resistant MDD received 36 treatments of Deep TMS-only (H1 + H7 protocols), while 66 received 36 treatments of Deep TMS (H1 + H7 protocols) and 6 IV infusions of ketamine over the course of 9 weeks. Depressive symptoms were compared pre- and -post treatment in both conditions using the PHQ-9. RESULTS: In both treatment groups, depressive symptoms were significantly reduced from pre-to-post and there were no significant differences in response between the TMS + ketamine condition and the TMS-only condition. The TMS + ketamine condition had an 80.30% response rate (53 out of 66) and 43.42% remission rate (28 out of 66) compared to a 76.92% response (130 out of 169) and 39.64% remission (67 out of 16) in the TMS-only condition. CONCLUSION: These results support the notion that TMS treatments yield high response rates in treatment-resistant cases; however, in this investigation there was no added benefit for including 6 sessions of IV ketamine in conjunction with TMS. Future investigations using randomized-control designs and robust outcome measures are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Delray Center for Brain Science, Delray Beach, FL, USA. nshanok@delraycenter.com.
- Delray Center for Brain Science, Delray Beach, FL, USA.
Zitieren
APA
Shanok, N. A., Muzac, S., Brown, L., Barrera, M., & Rodriguez, R. (2024). Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study. Psychopharmacology. https://doi.org/10.1007/s00213-024-06573-1
Vancouver
Shanok NA, Muzac S, Brown L, Barrera M, Rodriguez R. Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study. Psychopharmacology. 2024. doi:10.1007/s00213-024-06573-1
BibTeX
@article{Shanok2024,
author = {Shanok, Nathaniel A and Muzac, Sabrina and Brown, Leah and Barrera, Melissa and Rodriguez, Raul},
title = {Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study},
journal = {Psychopharmacology},
year = {2024},
doi = {10.1007/s00213-024-06573-1}
}
EUVIMED